Clinical Efficacy of Levothyroxine Sodium plus I 131 in the Treatment of Patients with Thyroidectomy and Its Effect on the Levels of Thyroglobulin and Thyrotropin.

This study was to evaluate the clinical efficacy of levothyroxine sodium tablets combined with I 131 in the treatment of patients after thyroidectomy and the effect on thyroglobulin (Tg) and thyroid stimulating hormone (TSH) levels. 80 patients with differentiated thyroid cancer who required thyroidectomy after surgery between July 2019 and January 2021 were recruited for prospective study, 40 patients in the control group received levothyroxine sodium tablets, and 40 patients in the experimental group received levothyroxine sodium treatment plus I 131 treatment. Treatment effect, serum Tg and TSH levels, and relapse were measured. The removal rate of residual thyroid tissue in the experimental group (87.50%) was significantly higher than that in the control group (57.50%) (P < 0.05). Levothyroxine sodium tablets plus I 131 was associated with a significantly higher efficacy versus levothyroxine sodium tablets (P < 0.05). There were no significant differences in the serum Tg levels between the two groups before treatment (P > 0.05). After treatment, the serum Tg levels in both groups were significantly decreased, and levothyroxine sodium tablets plus I 131 resulted in a significantly lower Tg level versus levothyroxine sodium tablets (P < 0.05). Before treatment, the two groups showed similar TSH levels (P > 0.05). After treatment, patients receiving levothyroxine sodium tablets plus I 131 had a significantly greater increase in the TSH levels versus levothyroxine sodium tablets (P < 0.05). The recurrence rate of the experimental group was lower than that of the control group (P < 0.05). Levothyroxine sodium tablets plus I 131 for post-operative patients with differentiated thyroid cancer enhance the removal rate of residual thyroid tissue, effectively reduce serum Tg level, and increase TSH level, with significant therapeutic effects, low recurrence rates, and a high safety profile.

Pang YL ，Wang YP ，Cheng K 《-》

Effectiveness and Safety of Levothyroxine Tablets Combined with Iodine-131 in the Treatment of Thyroid Cancer.

To explore the effectiveness of levothyroxine tablets combined with iodine-131 in thyroid cancer patients after radical thyroidectomy and the effect on their serum thyroglobulin (Tg) and thyroglobulin antibody (TgAb) levels. A total of 70 thyroid cancer patients receiving radical thyroidectomy in our hospital from July 2015 to April 2016 were recruited and were assigned via different treatment methods (1 : 1) to receive either levothyroxine tablets (observation group) or levothyroxine tablets plus iodine-131 (control group). Outcome measures included treatment efficiency, 1, 3, and 5-year recurrence and metastasis, serum Tg and TgAb levels, postoperative survival, and adverse reactions. The total effective rate of treatment in the control group was significantly higher than that in the observation group (P < 0.05). There was no significant difference in cancer recurrence and metastasis rate between the two groups one year postoperatively (P > 0.05). The rate of cancer recurrence and metastasis in the control group was significantly lower than that in the observation group 3 and 5 years after surgery (P < 0.05). Before treatment, there was no significant difference in serum Tg and TgAb levels between the two groups (P > 0.05). After treatment, serum Tg and TgAb levels decreased in both groups, with lower results in the control group (P < 0.05). There was no significant difference in the 1 and 3-year survival rates between the two groups (P > 0.05). The 5-year survival rate in the control group was significantly higher than that in the observation group (P < 0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05). Levothyroxine tablets combined with iodine-131 for thyroid cancer patients undergoing radical thyroidectomy effectively could improve the treatment efficiency, reduce the risk of cancer recurrence and metastasis after surgery, lower the serum Tg and TgAb levels of patients, and prolong the survival of patients, with a high safety profile. Further trials are, however, required prior to clinical promotion.

Bai Y ，Jin J ，Liu Y ，Zhang B ，Zhang B ，Li J ... -  《-》

Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.

Wang PW ，Wang ST ，Liu RT ，Chien WY ，Tung SC ，Lu YC ，Chen HY ，Lee CH ... -  《JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM》

Combined Efficacy of Modified Buqi Yangyin Sanjie Decoction and Levothyroxine Sodium Tablets on Thyroid Function and Immune Function Among Patients After Thyroid Cancer Surgery.

Zhou L ，Qin S ，Ba H ，Wang P ，Zhang Q ... -  《ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE》

Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?

Vera P ，Kuhn-Lansoy C ，Edet-Sanson A ，Hapdey S ，Modzelewski R ，Hitzel A ，d'Anjou J ，Basuyau JP ... -  《-》